Warfarin

An orally-available drug that has shown promise in the treatment of neurodegenerative diseases, including Alzheimer&rsquos disease and Huntington&rsquos disease.

A full agonist of the serotonin 5-HT1A receptor and antagonist of 5-HT2A (Kis = 1 and 49 nM, respectively) also binds to dopamine D4 receptors (Kis = 4-24 nM) reduces 5-HT in the prefrontal cortex and dorsal raphe of conscious rats while

An anti-coagulant differs from (&minus)-warfarin by being five times less potent as a vitamin K antagonist has a longer terminal elimination half-life (35-58 hours) than (&minus)-warfarin (24-33 hours).

A dual inhibitor of both PI3K and mTOR, completely blocking phosphorylation of substrates at 8-16 &microM induces cell death in GBM xenografts in vitro, with half maximal inhibition occurring at 3.7-7.

An analog of FTY720 that is a competitive antagonist of S1P1 has a Ki value of 0.69 &microM when assessed by SEW2871-induced activation of S1P1.

An orally-available drug that has shown promise in the treatment of neurodegenerative diseases, including Alzheimer&rsquos and Huntington&rsquos disease.

Synonyms: SC0030

A potent inhibitor of GSK3&beta (IC50 = 30 nM) that induces neurogenesis in mouse embryonic stem cells.

A cell-permeable aromatic amino-fluorescein derivative that can be oxidized and converted to fluorescein by ROS such as the hydroxyl radical, peroxynitrite, and ROS generated from a peroxidase/H2O2 system.

BW 245C is a selective agonist for the DP1 receptor. The Ki of BW 245C for the inhibition of [3H]-PGD2 binding to isolated human platelet membranes is 0.

A selective, irreversible JNK inhibitor (IC₅₀s = 4.67, 18.7, and 0.98 nM for JNK1, 2, and 3, respectively) prevents phosphorylation of c-Jun in A375 and HeLa cells (EC₅₀s = 338 and 486 nM, respectively).

An ATP-competitive inhibitor of JNK1, JNK2, and JNK3 (IC₅₀s = 150, 220, and 70 nM, respectively) effective in vivo in gerbils, mice, and rats via oral, intravenous, or intraperitoneal administration.